Company: RGNT
Filing Date: 2025-05-19
Form Type: F-1/A
Source: 0001213900-25-045479
Chunk: 254

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-05-19
Form: F-1/A
Chunk 254
---
| a. | Regentis Biomaterials Ltd. (the “Company”) commenced operations in September 2004.                                                       
 The Company develops innovative tissue repair solutions that seek to restore the health and enhance the quality of life of patients.     
 The Company’s current efforts are focused on orthopedic treatments using our Gelrin platform based on degradable hydrogel implants       
 to regenerate damaged or diseased tissue. Gelrin is a unique hydrogel matrix of polyethylene glycol diacrylate and denatured fibrinogen. 
 The Company’s lead product candidate is GelrinC, a cell-free, off-the-shelf hydrogel that is cured into an implant in the knee           
 for the treatment of painful injuries to articular knee cartilage.                                                                       |

| b. | Transaction with OceanTech Corp. |

On May 2, 2023, OceanTech Acquisitions
I Corp., a Delaware corporation (“OceanTech”), R.B. Merger Sub Ltd., an Israeli company and a wholly-owned subsidiary of
OceanTech (“Merger Sub”), Aspire Acquisition LLC, OceanTech’s sponsor (the “Sponsor”), and the Company
executed a definitive Agreement and Plan of Merger (the “Merger Agreement”) pursuant to which, among other things, Merger
Sub will merge with and into the Company (the “Merger”), with the Company surviving the Merger as a wholly owned subsidiary
of OceanTech. In May 2024, due to OceanTech not meeting certain Nasdaq compliance requirements, the Company and OceanTech couldn’t
proceed with the Merger and, as a result, the Merger Agreement was cancelled.

| c. | Forward share split |

On March 20, 2025, the Company effected a two and a half-for-one (2.5-for-1)
forward share split of its ordinary shares, no par value (the “Ordinary Shares”), and all classes of its preferred shares (the
“Split”). As a result of the Split, each one (1) Ordinary Share or preferred share, as applicable, issued and outstanding
at the time of the Split, was split into two and a half (2.5) Ordinary Shares or preferred shares, as applicable. All outstanding securities
entitling their holders the right to purchase Ordinary Shares, including, warrants and share options, were adjusted as a result of the
Split, as required by the terms of those securities. All share amounts, share prices, and exercise prices have been adjusted